# Sanja Đačić

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sanja-acic/

## Facts

| Field | Value |
| --- | --- |
| Citations | 27,629 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 73 |
| i10-index | 188 |
| Last Known Institution | Yale University |
| OpenAlex ID | https://openalex.org/A5102899480 |
| ORCID iD | https://orcid.org/0000-0003-4197-3354 |
| Works | 319 |

## Researcher papers

- [The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015](https://scholariq.org/papers/the-2021-who-classification-of-lung-tumors-impact-of-advances-since-2015/)
- [Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology](https://scholariq.org/papers/updated-molecular-testing-guideline-for-the-selection-of-lung-cancer-patients/)
- [PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project](https://scholariq.org/papers/pd-l1-immunohistochemistry-comparability-study-in-real-life-clinical-samples/)
- [A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee](https://scholariq.org/papers/a-grading-system-for-invasive-pulmonary-adenocarcinoma-a-proposal-from-the/)
- [IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy](https://scholariq.org/papers/iaslc-multidisciplinary-recommendations-for-pathologic-assessment-of-lung-cancer/)
- [Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer](https://scholariq.org/papers/best-practices-recommendations-for-diagnostic-immunohistochemistry-in-lung/)
- [PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee](https://scholariq.org/papers/pd-l1-testing-for-lung-cancer-in-2019-perspective-from-the-iaslc-pathology/)
- [The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?](https://scholariq.org/papers/the-2021-who-classification-of-tumors-of-the-thymus-and-mediastinum-what-is-new/)
- [The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee](https://scholariq.org/papers/the-promises-and-challenges-of-tumor-mutation-burden-as-an-immunotherapy/)
- [Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee](https://scholariq.org/papers/predictive-biomarkers-for-immunotherapy-in-lung-cancer-perspective-from-the/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Occupational and environmental lung diseases](https://scholariq.org/topics/occupational-and-environmental-lung-diseases/)
- [Medical Imaging and Pathology Studies](https://scholariq.org/topics/medical-imaging-and-pathology-studies/)

## Researcher university

- [Yale University](https://scholariq.org/institutions/yale-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.